Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096159
Filing Date
2024-08-13
Accepted
2024-08-13 16:05:32
Documents
86
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q gyre-20240630.htm   iXBRL 10-Q 2585359
2 EX-31.1 gyre-ex31_1.htm EX-31.1 16415
3 EX-31.2 gyre-ex31_2.htm EX-31.2 16329
4 EX-32.1 gyre-ex32_1.htm EX-32.1 12322
5 EX-32.2 gyre-ex32_2.htm EX-32.2 12316
  Complete submission text file 0000950170-24-096159.txt   11495060

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20240630.xsd EX-101.SCH 1513801
89 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20240630_htm.xml XML 2417971
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 241201354
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)